| SI No | Age | Sex | Organ  | pTNM    | Stage | Histology | Pathology  | Tissue Status | Species |
|-------|-----|-----|--------|---------|-------|-----------|--|---------------|---------|
| 1     | 66  | F   | Breast | T2N0M0  | IIA   |           | infiltrating duct carcinoma  | Tumor/cancer  | Human   |
| 2     | 43  | F   | Breast | T3N2aM0 | IIIA  |           | infiltrating duct carcinoma  | Tumor/cancer  | Human   |
| 3     | 58  | F   | Breast | T2N3aM0 | IIIA  |           | infiltrating duct carcinoma  | Tumor/cancer  | Human   |
| 4     | 46  | F   | Breast | T3N1aM0 | IIIB  |           | infiltrating duct carcinoma  | Tumor/cancer  | Human   |
| 5     | 71  | F   | Breast | T3N1aM0 | IIIA  |           | infiltrating<br>papillary<br>carcinoma with<br>signet ring cell<br>carcinoma | Tumor/cancer  | Human   |
| 6     | 37  | F   | Breast | T3N3aM0 | IIIA  |           | infiltrating duct carcinoma  | Tumor/cancer  | Human   |
| 7     | 53  | F   | Breast | T3N2aM0 | IIIA  |           | mixed infiltrating<br>duct and lobular<br>carcinoma                          | Tumor/cancer  | Human   |
| 8     | 30  | F   | Breast | T3N0M0  | IIB   |           | medullary<br>carcinoma   | Tumor/cancer  | Human   |
| 9     | 47  | F   | Breast | T2N1aM0 | IIB   |           | atypical<br>medullary<br>carcinoma   | Tumor/cancer  | Human   |
| 10    | 44  | F   | Breast | T2N0M0  | IIIA  |           | infiltrating ductal carcinoma  | Tumor/cancer  | Human   |
| 11    | 32  | М   | Liver  | тзиомо  | IIIA  |           | combined<br>hepatocellular<br>and<br>cholangiocarcino<br>ma                  | Tumor/cancer  | Human   |
| 12    | 57  | М   | Liver  | T3N0M0  | IIIA  |           | hepatocellular<br>carcinoma  | Tumor/cancer  | Human   |
| 13    | 58  | F   | Liver  | T3N0M0  | Ш     |           | hepatocellular<br>carcinoma  | Tumor/cancer  | Human   |
| 14    | 20  | М   | Liver  | T4N0M0  | IVA   |           | hepatocellular<br>carcinoma  | Tumor/cancer  | Human   |
| 15    | 63  | F   | Liver  | T1N0M0  | Ш     |           | hepatocellular<br>carcinoma  | Tumor/cancer  | Human   |
| 16    | 66  | F   | Liver  | T1N0M0  | П     |           | hepatocellular<br>carcinoma  | Tumor/cancer  | Human   |
| 17    | 61  | М   | Liver  | T1N0M0  | IIIA  |           | hepatocellular<br>carcinoma  | Tumor/cancer  | Human   |

| 18 | 52 | М | Liver              | T3N0M0  | IIIA |                                      | hepatocellular<br>carcinoma                           | Tumor/cancer | Human |
|----|----|---|--------------------|---------|------|--------------------------------------|---|--------------|-------|
| 19 | 50 | M | Liver              | T3N1M0  | IIIB |                                      | combined hepatocellular and cholangiocarcino ma       | Tumor/cancer | Human |
| 20 | 56 | М | Liver              | T3N0M0  | IIIA |                                      | hepatocellular<br>carcinoma                           | Tumor/cancer | Human |
| 21 | 53 | M | Urinary<br>bladder | T4bN0M0 | IV   |                                      | mucinous<br>adenocarcinoma<br>from urachal<br>remnant | Tumor/cancer | Human |
| 22 | 60 | М | Urinary<br>bladder | T3bN1M0 | IV   |                                      | transitional cell carcinoma                           | Tumor/cancer | Human |
| 23 | 60 | М | Urinary<br>bladder | T3bN1M0 | IV   |                                      | transitional cell carcinoma                           | Tumor/cancer | Human |
| 24 | 65 | М | Urinary<br>bladder | T4aN1M1 | IV   |                                      | transitional cell carcinoma                           | Tumor/cancer | Human |
| 25 | 74 | М | Urinary<br>bladder | T1N0M0  | I    |                                      | transitional cell carcinoma                           | Tumor/cancer | Human |
| 26 | 63 | F | Urinary<br>bladder | T1N0M0  | I    |                                      | transitional cell carcinoma                           | Tumor/cancer | Human |
| 27 | 58 | М | Urinary<br>bladder | T3NXM0  | Ш    |                                      | transitional cell carcinoma                           | Tumor/cancer | Human |
| 28 | 46 | М | Urinary<br>bladder | T1N0M0  | I    |                                      | transitional cell carcinoma                           | Tumor/cancer | Human |
| 29 | 76 | М | Urinary<br>bladder | T3NXM0  | Ш    |                                      | transitional cell carcinoma                           | Tumor/cancer | Human |
| 30 | 63 | М | Urinary<br>bladder | T3bN0M0 | III  |                                      | transitional cell carcinoma                           | Tumor/cancer | Human |
| 31 | 57 | F | Ovary              | T3bN1M0 | IIIC |                                      | serous<br>adenocarcinoma                              | Tumor/cancer | Human |
| 32 | 48 | F | Ovary              | T3cN0M0 | IIIC | moderatel<br>y<br>differentia<br>ted | serous<br>adenocarcinoma                              | Tumor/cancer | Human |
| 33 | 60 | F | Ovary              | T2cN0M0 | IIC  | poorly<br>differentia<br>ted         | serous surface<br>papillary<br>carcinoma              | Tumor/cancer | Human |
| 34 | 41 | F | Ovary              | T2cN1M0 | IIIC | moderatel<br>Y<br>differentia<br>ted | serous<br>adenocarcinoma                              | Tumor/cancer | Human |

| 35 | 64 | F | Ovary    | T3cN0M0 | IIIC |                                      | serous<br>adenocarcinoma   | Tumor/cancer | Human |
|----|----|---|----------|---------|------|--------------------------------------|----------------------------|--------------|-------|
| 36 | 60 | F | Ovary    | T3cN1M0 | IIIC |                                      | serous<br>adenocarcinoma   | Tumor/cancer | Human |
| 37 | 54 | F | Ovary    | T3aN0M0 | IIIA |                                      | serous<br>adenocarcinoma   | Tumor/cancer | Human |
| 38 | 58 | F | Ovary    | T2cN0M0 | IIC  |                                      | serous<br>adenocarcinoma   | Tumor/cancer | Human |
| 39 | 16 | F | Ovary    | T1aN0M0 | IA   |                                      | mucinous<br>adenocarcinoma | Tumor/cancer | Human |
| 40 | 57 | F | Ovary    | T3cN0M0 | IIIC | poorly<br>differentia<br>ted         | serous<br>adenocarcinoma   | Tumor/cancer | Human |
| 41 | 66 | M | Pancreas | T4N1M0  | IVA  | moderatel<br>Y<br>differentia<br>ted | ductal<br>adenocarcinoma   | Tumor/cancer | Human |
| 42 | 71 | M | Pancreas | T3N1M0  | 11   | moderatel<br>y<br>differentia<br>ted | ductal<br>adenocarcinoma   | Tumor/cancer | Human |
| 43 | 68 | M | Pancreas | T3N1M0  | Ш    | moderatel<br>y<br>differentia<br>ted | ductal<br>adenocarcinoma   | Tumor/cancer | Human |
| 44 | 45 | М | Pancreas | T3N1M0  | IVA  | moderatel<br>y<br>differentia<br>ted | ductal                     | Tumor/cancer | Human |
| 45 | 64 | F | Pancreas | T4N0M0  | IVA  | moderatel<br>y<br>differentia<br>ted | ductal<br>adenocarcinoma   | Tumor/cancer | Human |
| 46 | 64 | F | Pancreas | T3N1M0  | III  | moderatel<br>y<br>differentia<br>ted | ductal<br>adenocarcinoma   | Tumor/cancer | Human |
| 47 | 69 | M | Pancreas | T4NxM0  | IVA  | poorly<br>differentia<br>ted         | ductal<br>adenocarcinoma   | Tumor/cancer | Human |

| 48 | 46 | M | Pancreas | T3N1M0  | III | moderatel<br>y<br>differentia<br>ted | ductal<br>adenocarcinoma | Tumor/cancer | Human |
|----|----|---|----------|---------|-----|--------------------------------------|--------------------------|--------------|-------|
| 49 | 54 | M | Pancreas | T3N1M0  | Ш   | moderatel<br>Y<br>differentia<br>ted | ductal<br>adenocarcinoma | Tumor/cancer | Human |
| 50 | 40 | M | Pancreas | T3N1M0  | III | moderatel<br>Y<br>differentia<br>ted | ductal<br>adenocarcinoma | Tumor/cancer | Human |
| 51 | 85 | М | Prostate | TxN0M1  | IV  |                                      | adenocarcinoma           | Tumor/cancer | Human |
| 52 | 79 | М | Prostate | T2aN0M1 | IV  |                                      | adenocarcinoma           | Tumor/cancer | Human |
| 53 | 53 | М | Prostate | T2aN0M1 | IV  |                                      | adenocarcinoma           | Tumor/cancer | Human |
| 54 | 68 | М | Prostate | T2bN0M0 | IV  |                                      | adenocarcinoma           | Tumor/cancer | Human |
| 55 | 82 | М | Prostate | T2N0M1  | IV  |                                      | adenocarcinoma           | Tumor/cancer | Human |
| 56 | 76 | М | Prostate | T3aN0M0 | III |                                      | adenocarcinoma           | Tumor/cancer | Human |
| 57 | 56 | М | Prostate | T2cN1M0 | IV  |                                      | adenocarcinoma           | Tumor/cancer | Human |
| 58 | 66 | М | Prostate | T4N0M0  | IV  |                                      | adenocarcinoma           | Tumor/cancer | Human |
| 59 | 54 | М | Prostate | T1aN0M0 | I   |                                      | adenocarcinoma           | Tumor/cancer | Human |